摘要
目的探讨MUC1基因在血液系统恶性肿瘤中的作用机制、临床意义及在肿瘤生物治疗中的应用前景。方法应用半定量RT-PCR检测了55例血液系统恶性肿瘤患者的骨髓及外周血标本中MUC1基因的mRNA表达。其中多发性骨髓瘤(MM)10例、白血病21例、淋巴瘤24例,对照组外周血和骨髓各10例。结果10例MM患者MUC1mRNA阳性表达率为80%(8例),12例急性髓性白血病(AML)阳性表达率为58.3%(7例),均高于对照组的10%(1例)(P<0.05)。24例淋巴瘤患者阳性表达率54.1%(13例),其中非霍奇金淋巴瘤(NHL)阳性表达率52.4%(11例),霍奇金淋巴瘤(HD)阳性表达率66.7%(2例),均高于对照组0/10(0)(P<0.05)。MUC1高表达与AML患者的髓外浸润呈正相关,与淋巴瘤患者的分期呈正相关。结论MUC1mRNA在血液系统恶性肿瘤中高表达,其表达与血液系统恶性肿瘤的病情进展及预后相关。从mRNA水平为MUC1作为血液系统恶性肿瘤治疗性疫苗的研究提供有力的证据。
Objective To detect the expression of MUC1 gene in patients with hematological malignances and its clinical significance as well as immunotherapeutic possibility for these diseases. Methods The expression of MUC1 was detected in bone marrow and peripheral blood with the method of semiquantitative reverse transcriptase-polymerase chain reaction （RT-PCR） in 55 cases of hematological malignance, including 10 multiple myeloma, 21 acute myelogenous leukemia, and 24 lymphoma patients. 10 samples of the bone marrow and peripheral blood were detected respectively as controls. Results MUC1 expression in bone marrow was detected positive in 8 cases of 10 MM （80 %） and 7 cases of 12 AML（58.3 %）, which was significantly higher than that of the controls （P 〈0.05）. The expression of MUC1 in peripheral blood was detected positive in 13 lymphoma （54.2 %）,11NHL（52.4 %） and 2 HD（66.7 %）, which were significantly higher than that of the controls（P 〈0.05）. There existed a positive correlation between the expression of MUC1 and extramcdullary infiltration in AML and the stage of lymphoma. Conclusions The overexpression of MUC1 might play an important role in the progression of hematological malignances and may be a prognostic factor of these diseases. It might be used as a vaccine for hematological malignant diseases.
出处
《白血病．淋巴瘤》
CAS
2006年第6期438-441,共4页
Journal of Leukemia & Lymphoma
